Evidence map›Paper›PMID 42077005›Full record

ArticleStatistics in medicine2026

Proportional Hazards Regression for Interval-Censored Outcomes With an Interval-Censored Covariate.

Dongdong Li, Yue Song, Wenbin Lu, Huldrych F Günthard, Roger Kouyos, Rui Wang

Abstract read
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dongdong LiDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-4791-331X
Yue SongDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Wenbin LuDepartment of Statistics, North Carolina State University, Raleigh, North Carolina, USA.
Huldrych F GünthardDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Roger KouyosDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
Rui WangDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5007-193X

Funding

Modeling of Viral Load Trajectories for HIV Cure ResearchR01AI170254 · NIAID · HARVARD PILGRIM HEALTH CARE, INC. · PI WANG, RUI · 2022 to 2025
$1.6M
National Institute of Allergy and Infectious Diseases R01AI170254NIAID NIH HHS R01 AI170254
6 · The paper itself

Abstract

Identifying predictors for viral rebound trajectories after antiretroviral therapy (ART) interruption is central to HIV cure research. Motivated by the need to determine whether the time to achieve viral suppression after ART initiation can predict the time to viral rebound following ART interruption, we investigate modeling approaches that relate an interval-censored outcome (e.g., time to viral rebound) and an interval-censored covariate (e.g., time to viral suppression) under the assumption that viral load only crosses a threshold when bracketed by consecutive assessments. We develop estimation and inference procedures for fitting a proportional hazards regression model when both the outcome and a covariate are interval-censored, without imposing parametric assumptions on the baseline hazard functions. To accommodate participants with multiple episodes of ART initiation and interruption, we extend the proposed method to account for the clustering of repeated observations within individuals. We derive the asymptotic properties of the proposed method and evaluate its finite-sample performance through simulation studies. Applying the method to data from the Zurich Primary HIV Infection cohort, we find that a longer time to viral suppression during ART is associated with an increased hazard of viral rebound after ART interruption.

Indexed as

HIV InfectionsAnti-HIV AgentsAnti-Retroviral AgentsCohort StudiesComputer SimulationHumansProportional Hazards ModelsTime FactorsViral LoadAnti-HIV AgentsAnti-Retroviral Agentscomposite likelihoodEM algorithmHIV viral reboundinterval‐censored covariate

Identifiers

PMID42077005
PMCPMC13136924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.